A recent report from MarketsAndMarkets projected that the global gastric cancer market accounted for USD 3.01 billion in 2023 and is expected to reach USD 18.43 billion by 2034 with a CAGR of 17.92% ...

The Phase 1 trial is a randomized, double-blind, placebo-controlled study of single and multiple ascending doses of oral SCY-247 in approximately 100 healthy subjects. The primary endpoint is safety ...

As 2024 draws to a close, we explore five stocks to buy for a new year that promises opportunity alongside uncertainty ...

Biogen (BIIB) closed near a 52-week low of $150.03. The stock trades at a discount because the biotech firm lacks growth ...